Clinical Trials Directory

Trials / Completed

CompletedNCT00347503

Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
—
Sponsor
Innovative Medical · Industry
Sex
All
Age
21 Years
Healthy volunteers
Not accepted

Summary

Evaluation of the aqueous concentrations of 2 topical NSAIDS as well as the PGE2 inhibition in human patients.

Conditions

Interventions

TypeNameDescription
DRUGketorolac 0.4%, bromfenac 0.09%

Timeline

First posted
2006-07-04
Last updated
2007-07-13

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00347503. Inclusion in this directory is not an endorsement.

Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients (NCT00347503) · Clinical Trials Directory